<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9214">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05702827</url>
  </required_header>
  <id_info>
    <org_study_id>22-102</org_study_id>
    <nct_id>NCT05702827</nct_id>
  </id_info>
  <brief_title>Use of a Dual-agent Local Analgesic (Bupivacaine-meloxicam) for Abdominal Incisions in Patients Undergoing Retropubic Mid-urethral Sling Surgery</brief_title>
  <official_title>Use of a Dual-agent Local Analgesic (Bupivacaine-meloxicam) for Abdominal Incisions in Patients Undergoing Retropubic Mid-urethral Sling Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TriHealth Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TriHealth Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the use of a dual-agent local analgesic (bupivacaine-meloxicam) for&#xD;
      abdominal incisions in patients undergoing retropubic mid-urethral sling surgery to see if&#xD;
      narcotic usage and pain are impacted.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 23, 2023</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if use of bupivacaine-meloxicam reduces post-operative narcotic use over the first 3 days following surgery</measure>
    <time_frame>72 hours post surgery</time_frame>
    <description>Pain medication diary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare average pain on each day post operatively</measure>
    <time_frame>72 hours post surgery</time_frame>
    <description>11-point Numeric Rating Scale (NRS) for tracking pain using an illustrated figure to localize the pain, a 5-point Likert scale for satisfaction with pain control a Quality of Recovery (QoR-15) questionnaire filled out before surgery and on post-operative days 1 and 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare worst pain on each day post operatively</measure>
    <time_frame>72 hours post surgery</time_frame>
    <description>11-point Numeric Rating Scale (NRS) for tracking pain using an illustrated figure to localize the pain, a 5-point Likert scale for satisfaction with pain control a Quality of Recovery (QoR-15) questionnaire filled out before surgery and on post-operative days 1 and 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare satisfaction with pain control post operatively</measure>
    <time_frame>72 hours post surgery</time_frame>
    <description>11-point Numeric Rating Scale (NRS) for tracking pain using an illustrated figure to localize the pain, a 5-point Likert scale for satisfaction with pain control a Quality of Recovery (QoR-15) questionnaire filled out before surgery and on post-operative days 1 and 3</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Stress Urinary Incontinence</condition>
  <condition>Surgical Incision</condition>
  <condition>Pain Vulva</condition>
  <arm_group>
    <arm_group_label>bupivacaine-meloxicam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive a total of 20 cc lidocaine with epinephrine injection intra-operatively along the trocar path via the suprapubic incisions, as is standard practice to help with hydrodissection for the procedure. 3-4 cc of bupivacaine-meloxicam will be infiltrated into each suprapubic abdominal incision in the study group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>All patients will receive a total of 20 cc lidocaine with epinephrine injection intra-operatively along the trocar path via the suprapubic incisions, as is standard practice to help with hydrodissection for the procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine-Meloxicam</intervention_name>
    <description>All patients will receive standard of care but the study arm will also receive Bupivacaine-Meloxicam in addition.</description>
    <arm_group_label>bupivacaine-meloxicam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  undergoing retropubic mid-urethral sling surgery (with concomitant anterior repair or&#xD;
             urethrocele repair)&#xD;
&#xD;
          -  English as first language&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients undergoing concomitant posterior repair, vaginal vault suspension, or any&#xD;
             other intra-peritoneal surgeries including hysterectomy&#xD;
&#xD;
          -  NSAID use within 7 days of surgery&#xD;
&#xD;
          -  steroid use within 10 days&#xD;
&#xD;
          -  daily opioid use in the last 3 months&#xD;
&#xD;
          -  long acting opioids within 3 days&#xD;
&#xD;
          -  any opioids within 24h&#xD;
&#xD;
          -  patients unable to consent for themselves&#xD;
&#xD;
          -  patients allergic to meloxicam or bupivacaine&#xD;
&#xD;
          -  pregnant or lactating patients&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mildrede Bonglack, MD</last_name>
    <phone>513-463-4300</phone>
    <email>mildrede_bonglack@trihealth.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cincinnati Urogynecology Associates</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Hodge, RN</last_name>
      <phone>513-463-4300</phone>
      <email>Jennifer_Hodge2@trihealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Trihealth (Good Samaritan Hospital, Bethesda North Hospital)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Hodge</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>January 18, 2023</study_first_submitted>
  <study_first_submitted_qc>January 18, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2023</study_first_posted>
  <last_update_submitted>March 27, 2023</last_update_submitted>
  <last_update_submitted_qc>March 27, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
    <mesh_term>Surgical Wound</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meloxicam</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

